focus -WSS

focus

author：knowledge 2025-09-03 05:26:00 - browse：2998

Illustration of a red human heart with an EKG line in the middle. -- health coverage from STAT — Adobe

Just weeks after Novo Nordisk announced that its obesity drug Wegovy cut the risk of heart complications in a major trial, the company now has results from a different study showing the treatment can also benefit people with a common type of heart failure.

The results, published Friday in the New England Journal of Medicine, found that among people with obesity and heart failure with preserved ejection fraction, or HFpEF, those taking Wegovy experienced greater improvements in symptoms and physical function compared with those on placebo. The improvements were greater than what’s been seen in trials of some other HFpEF treatments.

Novo previously shared topline results in investor calls, but the new study contains the full findings, which are also being presented at the European Society of Cardiology conference this week.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Why health care costs have stayed mostly flat since 2010

knowledge

WSS

Prime Medicine, Myeloid Therapeutics clash over genome

Threats against the LGBTQIA+ community intensifying: Department of Homeland Security

Editas, Vertex strike deal on CRISPR

Keeping primary care docs in field isn't impossible, says AAFP CEO

Iowa House, Senate pass 6

Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

knowledge

focus

leisure time

How one medical school became remarkably diverse

Albert Bourla of Pfizer: worst biopharma CEO of 2023

George Santos makes 1st court appearance after pleading not guilty to 13 counts

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Continuity nursing helped my family in our darkest PICU moments

HCA sued by state AG for quality issues at Mission Health

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

CRISPR gene editing developments we’re watching in 2024

As demand for Covid shots wanes, Moderna seeks its next success

Medicare drug price negotiation hasn't dried up venture capital

Wikipedia

Prime Medicine, Myeloid Therapeutics clash over genome

Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

Retired US general questions alleged Putin, Prigozhin meeting

Palantir health business leans on meeting customers’ needs

Why ADHD is under

Drinking less cuts risk of oral cavity, esophageal cancer: Report

knowledge

hotspot

leisure time

Wikipedia